INCY

Incyte Corporation Press Releases

$105.51
*  
3.85
3.79%
Get INCY Alerts
*Delayed - data as of Apr. 20, 2015  -  Find a broker to begin trading INCY now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    INCY Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By











Verastem Reports Year-End 2014 Financial Results
3/10/2015 7:00:00 AM - Business Wire










Incyte to Present at Upcoming Investor Conferences
2/17/2015 8:00:00 AM - Business Wire






Incyte Announces Publication of Phase III RESPONSE Trial in Patients with Polycythemia Vera in New England Journal of Medicine
1/28/2015 5:00:00 PM - Business Wire
▲29.56 % Price Change since this news event. The Volume Ratio is 0.01.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Incyte to Report Fourth Quarter/Year-End 2014 Financial Results on February 12
1/27/2015 8:00:00 AM - Business Wire
▲27.18 % Price Change since this news event. The Volume Ratio is 0.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Incyte Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Approval in Europe for Polycythemia Vera
1/23/2015 7:35:00 AM - Business Wire
▲35.95 % Price Change since this news event. The Volume Ratio is 1.22.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day